Modeling Principle

The Mouse KARPAS‑422 Model is a xenograft tumor model established by inoculating human KARPAS‑422 diffuse large B‑cell lymphoma cells (activated B‑cell subtype ABC‑DLBCL) into immunodeficient mice. KARPAS‑422 is derived from human non‑Hodgkin lymphoma pleural effusion, bearing typical molecular signatures of ABC‑DLBCL with constitutive NF‑κB activation and aberrant B‑cell receptor signaling. The cell line is responsive to B‑cell pathway inhibitors, BTK inhibitors, BCL‑2 inhibitors, anti‑CD20 antibodies and chemotherapeutic agents, recapitulating biological phenotypes of clinical ABC‑subtype diffuse large B‑cell lymphoma. Since human tumor cells cannot survive in immunocompetent mice, severely immunodeficient mice are applied to eliminate host rejection, enabling stable subcutaneous growth or systemic disseminated lymphoma. Subcutaneous xenografts facilitate tumor volumetric quantification and high‑throughput pharmacodynamic screening; intravenous injection generates disseminated lymphoma mimicking clinical bone‑marrow, spleen and peripheral blood infiltration. This model is widely utilized for pre‑clinical in‑vivo efficacy evaluation of novel DLBCL‑targeted agents, chemo‑targeted combination regimens, antibody drugs and CAR‑T therapy, as well as signaling‑pathway mechanistic dissection. It serves as a mainstream SCI gold‑standard in‑vivo model for translational research of non‑Hodgkin B‑cell lymphoma and can be directly applied for grant proposals, dissertations and manuscript methodology sections.

Model Validation Criteria

Quantitative Criteria for Tumor Formation and Growth

1. Subcutaneous model take‑rate: Tumor take‑rate ≥90 % within 2‑3 weeks post‑inoculation; tumor volume >50 mm³ is defined as successful engraftment. Vehicle‑control tumors exhibit sustained and stable growth reaching average 600‑1200 mm³ at week 3. Intra‑group coefficient of variation (CV) of tumor volume <30 % indicates satisfactory reproducibility.
2. Disseminated model: Human‑derived CD19⁺CD45⁺ lymphoma cells are detectable in peripheral blood, bone‑marrow and spleen by flow cytometry. Animals develop progressive weight loss and reduced activity followed by mortality, yielding well‑separated survival curves.
3. Positive‑control validation: Positive‑control group achieves TGI≥40 % (subcutaneous) or significantly prolonged median survival versus model group (P＜0.05), confirming sensitive response to pharmacological intervention and valid model establishment.

Histopathological and Molecular Gold‑Standard Indexes

1. HE staining: Tumor consists of abundant atypical lymphoid cells with enlarged hyperchromatic nuclei, frequent mitotic figures and focal necrosis. In disseminated model, human‑lymphoma infiltrates are observed in spleen and bone‑marrow.
2. Immunohistochemistry: Tumor tissue shows strong human‑specific CD19 and CD20 positivity with high Ki‑67 proliferation index and NF‑κB pathway activation, recapitulating ABC‑DLBCL molecular features.
3. Pharmacodynamic phenotype validation: Treatment group demonstrates reduced Ki‑67 index, elevated Cleaved‑caspase‑3 and suppressed NF‑κB activity compared with vehicle control. Flow cytometry confirms reduced lymphoma burden. In‑vivo observations are cross‑validated with in‑vitro cellular results.

Academic Evidence for Model Validity

Core validation evidence for KARPAS‑422 model: ① NSG mice support stable engraftment of human ABC‑DLBCL KARPAS‑422 with high subcutaneous take‑rate and capability to establish systemic disseminated lymphoma; ② xenografts retain key ABC‑DLBCL molecular hallmarks including constitutive NF‑κB activation and responsiveness to clinical targeted agents; ③ inter‑individual variation of tumor growth is controllable for statistical inference; ④ positive‑control agents produce robust anti‑tumor effects verifying assay sensitivity; ⑤ multi‑dimensional readouts including solid‑tumor volumetry, disseminated tumor burden, survival analysis and pathological‑molecular mechanism are achievable. This model is suitable for pre‑clinical translational research of novel agents against ABC‑subtype diffuse large B‑cell lymphoma.

Model Advantages

KARPAS‑422 is a globally widely‑used ABC‑DLBCL xenograft model faithfully recapitulating key molecular phenotypes of activated‑B‑cell‑like diffuse large B‑cell lymphoma with constitutive NF‑κB activation, suitable for evaluating BTK, BCL‑2 and anti‑CD20‑antibody‑based therapeutics. Both subcutaneous solid tumors for high‑throughput screening and systemic disseminated lymphoma mimicking clinical dissemination can be established. The cell line is easy to culture with stable engraftment. Multi‑modal readouts including tumor growth, survival, flow‑cytometric tumor burden, histopathology and molecular‑pathway analysis are supported. Experimental outputs are well‑accepted by hematological‑oncology SCI journals and applicable for NSFC grants, postgraduate proposals and manuscript methodology chapters.

Research Applications

The Mouse KARPAS‑422 Model is mainly applied for pre‑clinical in‑vivo efficacy assessment of ABC‑subtype diffuse large B‑cell lymphoma (non‑Hodgkin B‑cell lymphoma). It evaluates anti‑tumor activities of BTK inhibitors, BCL‑2 inhibitors, anti‑CD20 antibodies, novel small‑molecule compounds, chemotherapeutic monotherapies and combination regimens. It dissects regulatory mechanisms of B‑cell‑receptor, NF‑κB and BCL‑2‑family signaling pathways. Subcutaneous xenografts support high‑throughput drug screening, while tail‑vein disseminated models mimic hematogenous spread and bone‑marrow infiltration. It supports hematological‑oncology new‑drug development, NSFC grant applications, postgraduate dissertations and SCI manuscript methodology sections, serving as a mainstream pre‑clinical gold‑standard in‑vivo model for ABC‑DLBCL research.

Mouse KARPAS‑422 model, diffuse large B‑cell lymphoma, DLBCL xenograft model, ABC‑DLBCL, in‑vivo lymphoma pharmacodynamics, B‑cell malignancy, targeted drug screening, lymphoma immunopathology, pre‑clinical non‑Hodgkin lymphoma model